EUVIMEDEUVIMED entdecken
Klinische StudieMultizentrische StudieOpen Access · CC BY 4.0

Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer

Apostolia M Tsimberidou iD, Farah A Alayli iD, Kwame Okrah iD, Alexandra Drakaki iD, Danny N Khalil iD, Shivaani Kummar iD, Saad A Khan iD, F Stephen Hodi iD, David Y Oh iD, Christopher R Cabanski iD, Shikha Gautam iD, Stefanie L Meier iD und 28 weitere

Journal of Experimental Medicine · 07.10.2024 · 221 (10)

DOI: 10.1084/jem.20240152 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Journal of Experimental Medicine, online erschienen am 27.08.2024. Verfasst von Apostolia M Tsimberidou und 39 weiteren Autor:innen. Beteiligte Einrichtung: Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Drug Resistance, Neoplasm, Ipilimumab, Nivolumab. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Parker Institute for Cancer Immunotherapy, Bristol Myers Squibb.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Identifying pan-tumor biomarkers that predict responses to immune checkpoint inhibitors (ICI) is critically needed. In the AMADEUS clinical trial (NCT03651271), patients with various advanced solid tumors were assessed for changes in intratumoral CD8 percentages and their response to ICI. Patients were grouped based on tumoral CD8 levels: those with CD8 <15% (CD8-low) received nivolumab (anti-PD-1) plus ipilimumab (anti-CTLA4) and those with CD8 ≥15% (CD8-high) received nivolumab monotherapy. 79 patients (72 CD8-low and 7 CD8-high) were treated. The disease control rate was 25.0% (18/72; 95% CI: 15.8–35.2) in CD8-low and 14.3% (1/7; 95% CI: 1.1–43.8) in CD8-high. Tumors from 35.9% (14/39; 95% CI: 21.8–51.4) of patients converted from CD8 <15% pretreatment to ≥15% after treatment. Multiomic analyses showed that CD8-low responders had an inflammatory tumor microenvironment pretreatment, enhanced by an influx of CD8 T cells, CD4 T cells, B cells, and macrophages upon treatment. These findings reveal crucial pan-cancer immunological features for ICI response in patients with metastatic disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD8-Positive T-LymphocytesDrug Resistance, NeoplasmIpilimumabNivolumabAdultAgedFemaleHumansMaleMiddle AgedImmune Checkpoint InhibitorsNeoplasm MetastasisNeoplasmsTumor Microenvironment

Substanzen

Immune Checkpoint InhibitorsIpilimumabNivolumab

Autor:innen und Institutionen

  • Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Parker Institute for Cancer Immunotherapy , San Francisco, CA, USA.
  • University of California, Los Angeles , Los Angeles, CA, USA.
  • Memorial Sloan Kettering Cancer Center , New York, NY, USA.
  • Stanford University , Stanford, CA, USA.
  • Dana-Farber Cancer Institute , Boston, MA, USA.

ORCID-Profile: Apostolia M Tsimberidou, Farah A Alayli, Kwame Okrah, Alexandra Drakaki, Danny N Khalil, Shivaani Kummar, Saad A Khan, F Stephen Hodi, David Y Oh, Christopher R Cabanski, Shikha Gautam, Stefanie L Meier, Meelad Amouzgar, Shannon M Pfeiffer, Robin Kageyama, EnJun Yang, Marko Spasic, Michael T Tetzlaff, Wai Chin Foo, Travis J Hollmann, Yanyun Li, Matthew Adamow, Phillip Wong, Jonni S Moore, Sharlene Velichko, Richard O Chen, Dinesh Kumar, Samantha Bucktrout, Ramy Ibrahim, Ute Dugan, Lisa Salvador, Vanessa M Hubbard-Lucey, Jill O'Donnell-Tormey, Sandra Santulli-Marotto, Lisa H Butterfield, Diane M Da Silva, Justin Fairchild, Theresa M LaVallee, Lacey J Padrón, Padmanee Sharma

Förderung

  • NCI NIH HHS
  • Parker Institute for Cancer Immunotherapy
  • Bristol Myers Squibb
  • Cancer Research Institute

Zitieren

APA

Tsimberidou, A. M., Alayli, F. A., Okrah, K., Drakaki, A., Khalil, D. N., Kummar, S., Khan, S. A., Hodi, F. S., Oh, D. Y., Cabanski, C. R., Gautam, S., Meier, S. L., Amouzgar, M., Pfeiffer, S. M., Kageyama, R., Yang, E., Spasic, M., Tetzlaff, M. T., Foo, W. C., …, & Sharma, P. (2024). Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer. Journal of Experimental Medicine, 221(10). https://doi.org/10.1084/jem.20240152

Vancouver

Tsimberidou AM, Alayli FA, Okrah K, Drakaki A, Khalil DN, Kummar S, et al. Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer. Journal of Experimental Medicine. 2024;221(10). doi:10.1084/jem.20240152

BibTeX
@article{Tsimberidou2024,
  author = {Tsimberidou, Apostolia M and Alayli, Farah A and Okrah, Kwame and Drakaki, Alexandra and Khalil, Danny N and Kummar, Shivaani and Khan, Saad A and Hodi, F Stephen and Oh, David Y and Cabanski, Christopher R and Gautam, Shikha and Meier, Stefanie L and Amouzgar, Meelad and Pfeiffer, Shannon M and Kageyama, Robin and Yang, EnJun and Spasic, Marko and Tetzlaff, Michael T and Foo, Wai Chin and Hollmann, Travis J and Li, Yanyun and Adamow, Matthew and Wong, Phillip and Moore, Jonni S and Velichko, Sharlene and Chen, Richard O and Kumar, Dinesh and Bucktrout, Samantha and Ibrahim, Ramy and Dugan, Ute and Salvador, Lisa and Hubbard-Lucey, Vanessa M and O'Donnell-Tormey, Jill and Santulli-Marotto, Sandra and Butterfield, Lisa H and Da Silva, Diane M and Fairchild, Justin and LaVallee, Theresa M and Padrón, Lacey J and Sharma, Padmanee},
  title = {Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer},
  journal = {Journal of Experimental Medicine},
  year = {2024},
  volume = {221},
  number = {10},
  doi = {10.1084/jem.20240152}
}
Kostenlos starten →